Vercirnon

Drug Profile

Vercirnon

Alternative Names: CCX-282; CCX-282B; GSK'786; GSK-1605786; GSK-1605786-A; Traficet-EN

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; GlaxoSmithKline
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Crohn's disease; Ulcerative colitis
  • No development reported Coeliac disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Oct 2014 Efficacy and adverse events data from the phase III SHIELD-4 trial in Crohn's disease presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG-2014)
  • 19 May 2014 Vercirnon is available for licensing as of 19 May 2014. http://www.chemocentryx.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top